Ulpan Amzeyeva | Biomedicine | Young Scientist Award

Published on by Molecular Biologist

Ms. Ulpan Amzeyeva | Biomedicine | Young Scientist Award 

Research Assistant | The Research Center for Medicinal Plants, Al-Farabi Kazakh National University | Kazakhstan

Ms. Ulpan Amzeyeva is a Kazakhstani researcher specializing in natural product chemistry, phytochemistry, nanomaterials, and biomedical applications. Her interdisciplinary background spans nanotechnology, chemical physics, biomedicine, and biology, contributing to advances in medicinal plant research, biomaterials, sorbents, and functional food technologies. She serves as a researcher at the Research Center for Medicinal Plants at Al-Farabi Kazakh National University, focusing on biotechnology, natural compounds, and translational approaches for improving human and animal health. Her academic training covers nanomaterials, chemistry, pedagogical sciences, and biology, supported by progressive research and technical appointments in industrial biotechnology, sorbent development, and functional food innovation. Her interests include phytochemistry, nanostructured materials, biomedical engineering, compound profiling techniques, and bioactivity studies. She has taken part in nationally supported scientific programs, international training initiatives, and multidisciplinary research projects. Alongside her publications, she is a co-author of patents related to sorbent materials, biomedical dressings, composite structures, and functional food formulations. Her scholarly record includes 13 citations from 13 documents, 7 indexed publications, and an h-index of 2.

Profiles: Scopus | ORCID

Featured Publications

Baiseitova, A., Amzeyeva, U., et al. Response surface methodology optimization on ultrasonic-assisted extraction of chicory (Cichorium intybus L.) and UPLC-ESI-QTOF-MS analysis. Journal eFood (Q1).
Cited by (Scopus): Use “Cited by” filter in Scopus.

Minkayeva, A. A., Azilbek, L., Amzeyeva, U., et al. Comparative investigation of Rheum tataricum and Rheum palmatum. International Journal of Biology and Chemistry.
Cited by: Pending indexing.

Minkayeva, A. A., Mamashev, S., Nurlybekova, A., Amzeyeva, U., et al. Chemical constituents of Dianthus superbus, Matricaria chamomilla and Glycyrrhiza glabra. IJBC, 2(16).
Cited by: Check Scopus database.

Kazymbetova, A., Amzeyeva, U., et al. Secondary Metabolites and Cytotoxic Activity of Artemisia nitrosa and A. marschalliana. Molecules, 27(22).
Cited by (Scopus): Available in journal metrics.

Nuraly, A., Amzeyeva, U., et al. Comparative analysis of hemosorbents obtained at different modes. Revista Materia, 25(4).
Cited by: Scopus listing available.

jinghui xie | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Mr. jinghui xie | Molecular Biology | Best Researcher Award 

Associate professor, at xinjiang medical university, China.

Dr. Jinghui Xie is an accomplished researcher and Associate Professor in the Department of Biochemistry and Molecular Biology at Xinjiang Medical University.  He holds a Doctor of Science (Ph.D.) and Master of Science from Nankai University, and a Bachelor of Science from Shihezi University. His research focuses on the pathogenesis and treatment of diabetic microvascular lesions, with a strong emphasis on stem cell therapy, tissue engineering, and vascular organoid modeling.  Dr. Xie has been a recipient of the prestigious “Tianchi Talents Young Doctoral Program” of the Xinjiang Uygur Autonomous Region and has successfully led several major regional and national scientific research projects. 🔬 With 6 SCI-indexed papers in top-tier international journals like Journal of Materials Chemistry B and ACS Biomaterials Science & Engineering, along with 2 impactful Chinese publications, he is making significant contributions to translational medicine. His work bridges the gap between biomaterials, regenerative medicine, and clinical applications for diabetic complications.

Professional Profile

Google Scholar

🎓 Education

Dr. Xie’s academic journey reflects a progressive pursuit of excellence in biomedical science. 📖 He earned his Bachelor of Science from Shihezi University, laying the foundation in biochemistry and molecular biology. He then pursued Master of Science at Nankai University, where he honed his expertise in biomaterials and regenerative medicine. 🧪 His scholarly curiosity and dedication to advancing diabetic microvascular disease treatment led him to achieve a Doctor of Science (Ph.D.) in Biochemistry and Molecular Biology at Nankai University. During his Ph.D., he focused on vascular tissue engineering and stem cell-based therapies, resulting in several high-impact publications and innovative methodologies. 🎯 Throughout his education, he gained multidisciplinary knowledge combining biomedical engineering, molecular biology, and clinical research, equipping him with a solid background for cutting-edge research. 🎓💡

💼 Experience

Dr. Xie currently serves as an Associate Professor at the Department of Biochemistry and Molecular Biology, Xinjiang Medical University, where he mentors young researchers and leads multiple interdisciplinary projects. 👨‍🏫 He is the Principal Investigator (PI) of major funded studies, including the Natural Science Foundation Youth Project of the Xinjiang Uygur Autonomous Region and the Tianchi Talents Young Doctoral Program. 🏗️ His ongoing research includes mechanistic studies of engineered human mesenchymal stem cells for diabetic microvascular disease and construction of vascular organoid models. He has also contributed as a key participant in several National Natural Science Foundation of China (NSFC) projects on bioresponsive hydrogels, liver organoids, and neurovascular tissue engineering. 🔬 Beyond research, Dr. Xie actively contributes to academic development through teaching, curriculum improvement, and editorial roles in medical education journals. 🏅

🔬 Research Interests

Dr. Xie’s research is deeply rooted in regenerative medicine, biomaterials, and vascular biology. His primary focus is on the pathogenesis and treatment of diabetic microvascular lesions, exploring how engineered human mesenchymal stem cells (hMSCs) and biofunctionalized hydrogels can repair damaged vasculature. 💉 He is also advancing the construction of organoid models, such as vascular organoids, to study endothelial-pericyte interactions and mimic pathological conditions. 🌱 His work integrates stem cell therapy, bioresponsive biomaterials, and tissue engineering scaffolds to develop novel therapeutic approaches for diabetic complications, cardiovascular diseases, and tissue regeneration. He also explores VE-cadherin and N-cadherin functionalized matrices to promote angiogenesis and endothelial differentiation. 🧪 His long-term goal is to translate biomaterial-based therapies into clinical applications, improving the quality of life for diabetic patients. 🌟

🏆 Awards & Honors

Dr. Xie is the proud recipient of the Tianchi Talents Young Doctoral Program Award, a prestigious recognition by the Xinjiang Uygur Autonomous Region, which supports outstanding young researchers with innovative medical research projects. 🏅 He has also secured multiple competitive grants, including the Natural Science Foundation of the Autonomous Region Youth Project and funding from the Central Asian High Incidence Causes and Prevention State Key Laboratory. 💡 His impactful research has been acknowledged in top-tier SCI journals, leading to citations and collaborations within the international scientific community. 🌍 Furthermore, his invention patents in biomaterial functionalization and 3D cell culture systems demonstrate his contribution to translational research and medical innovation. 🚀

📚 Top Noted Publications 

Dr. Xie has authored 6 SCI-indexed papers in internationally recognized journals, such as Journal of Materials Chemistry B and ACS Biomaterials Science & Engineering, and 2 additional Chinese-language articles. His publications span topics including hydrogel-based tissue engineering, endothelial differentiation of hMSCs, and vascular organoid modeling. 📖 His work on VE-cadherin functionalized matrices has been widely cited in studies on angiogenesis and regenerative medicine. ✨ Additionally, he holds 3 invention patents, showcasing novel biomaterial-based methods for vascular tissue regeneration. His research contributions have been cited in applied biomaterials, cardiovascular therapy, and diabetes-related tissue engineering studies, reinforcing his influence in the field. 🌐

🔗 Representative Publications with Citation Prompt

📄 1️⃣ Lv C, Li S, Sang M, Cui T, Xie J.
Title: Construction of Microsphere Culture System for Human Mesenchymal Stem Cell Aggregates
Journal: International Journal of Molecular Sciences
Year: 2025, Volume 26, Article 6435
Link: 🔗 Read Here
Citation Context: Frequently cited in organoid culture system research for its innovative approach to MSC aggregate formation.

📄 2️⃣ Jinghui Xie, Xiaoning Li, Yan Zhang, et al.
Title: VE-Cadherin based matrix promoting self-reconstruction of proangiogenic microenvironment
Journal: Journal of Materials Chemistry B
Year: 2021, 9(1), pp. 3357–3370
Link: 🔗 Read Here
Citation Context: Referenced in endothelial differentiation studies exploring angiogenic microenvironments.

📄 3️⃣ Yuanning Lyu, Jinghui Xie, Yang Liu, et al.
Title: Injectable Hyaluronic Acid Hydrogel for Myocardial Repair
Journal: ACS Biomaterials Science & Engineering
Year: 2020, 6(12), pp. 6926–6937
Link: 🔗 Read Here
Citation Context: Widely cited in cardiac tissue regeneration research as a promising hydrogel-based therapy.

📄 4️⃣ Yang Jun, Xie Jinghui, Gao Chao, et al.
Title: VE-cad-Fc Functionalized Hyaluronic Acid Hydrogel
Journal: Journal of Tianjin University
Year: 2019, 52(1), pp. 33–39
Link: 🔗 Read Here
Citation Context: Referenced in biomaterial surface engineering papers for endothelial-friendly hydrogel design.

📄 5️⃣ Chao Gao, Yan Zhang, Jinghui Xie, et al.
Title: VE-cadherin functionalized injectable hydrogel promotes endothelial differentiation
Journal: Applied Materials Today
Year: 2020, Volume 20, Article 100690
Link: 🔗 Read Here
Citation Context: Frequently cited in angiogenesis hydrogel studies for vascular tissue engineering.

📄 6️⃣ Ke Xu, Chuanshun Zhu, Jinghui Xie, et al.
Title: Enhanced Vascularization of PCL Scaffolds through VEGF-Fc
Journal: Journal of Materials Chemistry B
Year: 2018, 6(6), p. 4485
Link: 🔗 Read Here
Citation Context: Referenced in scaffold vascularization research for improved angiogenic responses.

🏆 Conclusion

This researcher is highly suitable for a Best Researcher Award, particularly in biomaterials, regenerative medicine, and diabetic vascular disease research. Their combination of funded projects, impactful publications, and patents demonstrates innovation and leadership.

Marija Gjorgoska | Molecular Diagnostics | Best Researcher Award

Published on by Molecular Biologist

Ms. Marija Gjorgoska | Molecular Diagnostics | Best Researcher Award 

Asistant, at Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Slovenia.

Marija Gjorgoska is a dedicated biochemist and molecular biologist specializing in cancer research and steroid hormone signaling. Currently a Teaching and Research Assistant at the Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, she contributes to both education and cutting-edge biomedical research. With a strong foundation in LC-MS/MS and bioinformatics, Marija’s work focuses on cancer tissue analysis and hormone-related pathophysiology. Her academic journey spans prestigious institutions in Slovenia, Spain, and Macedonia, earning top grades and fellowships. She has authored impactful scientific papers in high-impact journals and has trained internationally, including at the University of Birmingham. Marija combines analytical precision with a passion for advancing women’s health, particularly in gynecological cancers. Her work bridges bench research and clinical relevance, making her a valuable voice in molecular medicine. Fluent in four languages and equipped with versatile lab skills, Marija continues to contribute meaningfully to biomedical innovation. 🌍🧪📚

Professional Profile

Scopus

🎓 Education

Marija Gjorgoska’s academic journey is marked by interdisciplinary excellence. She is currently pursuing her PhD in Biomedicine with a focus on Biochemistry and Molecular Biology at the University of Ljubljana. Prior to this, she completed an MSc in Molecular Biology at the same university with a remarkable GPA of 9.52/10. Her academic endeavors also led her to Spain, where she earned an MSc in Neuroscience from Universidad Miguel Hernandez under the prestigious Severo Ochoa fellowship, graduating in the top 15% of her class. Her foundational education was a BSc in Biochemistry and Physiology at the University “Ss. Cyril and Methodius”, Macedonia, where she was recognized as the best student of her generation with a GPA of 9.74/10. Her diverse academic background across biochemistry, neuroscience, and molecular biology forms the basis of her integrative approach to biomedical research. 📖🧬🎓

🧪 Experience

Marija Gjorgoska currently holds dual roles at the University of Ljubljana’s Faculty of Medicine—as a Teaching Assistant and a Research Assistant. Since 2020, she has led critical efforts in LC-MS/MS method development and validation, genetic and proteomic cancer tissue analysis, and R-based bioinformatics. She actively supports literature review, manuscript preparation, and educational delivery. Her teaching spans courses such as Principles of Biochemistry and practical instruction for medical and PhD students in LC-MS/MS and steroid hormone biochemistry. Marija has also conducted laboratory teaching in General Biochemistry at her alma mater in Macedonia. Her professional development includes internships at the University of Birmingham’s Institute of Metabolism and the Macedonian Academy of Sciences and Arts, where she worked on rare diseases and HPV screening. Her hands-on expertise, leadership in research, and global training have made her an invaluable contributor to both education and science. 🔬📊👩‍🏫

🔬 Research Interests 

Marija’s research is rooted in translational biochemistry with a strong focus on hormonal signaling in cancer. She specializes in steroid hormones, particularly estrogen and androgens, and their role in gynecological malignancies such as ovarian and endometrial cancers. Her work employs advanced liquid chromatography-tandem mass spectrometry (LC-MS/MS) to simultaneously profile endogenous steroid hormones. In addition, she explores the tumor microenvironment, cancer metabolism, and pre-receptor regulation mechanisms. Her recent studies delve into multi-steroid profiling combined with machine learning to identify novel biomarkers, demonstrating her innovative approach. She is also involved in Mendelian randomization to explore causal links between hormones and disease subtypes. Marija is deeply motivated to enhance the molecular understanding of hormone-related pathologies, aiming for clinical translation. Her interdisciplinary research bridges molecular biology, analytical chemistry, and bioinformatics, making significant contributions to cancer diagnostics and therapeutics. 🧬💉📈

🏆 Awards 

Marija Gjorgoska’s academic excellence and research innovation have been recognized through several prestigious awards. In 2023, she received the Practical Skills Grant from the Society of Endocrinology, UK, acknowledging her practical training in LC-MS/MS techniques. In 2021, her Master’s thesis on molecular biology earned her the Krka Recognition with Special Praise, awarded to outstanding postgraduate researchers in Slovenia. Her consistent top academic performance includes graduating among the top 15% in her neuroscience MSc program in Spain and being named the best student of the generation during her BSc studies in Macedonia. These honors reflect her exceptional academic record, technical expertise, and contributions to biomedical research. Her recognition at both national and international levels highlights her as a rising star in molecular medicine, particularly in cancer biochemistry and hormone signaling. 🏅🎖️📜

📚Top Noted  Publications 

✅ 1. Gjorgoska, M., & Lanišnik-Rižner, T. (2024)

Title: From fallopian tube epithelium to high-grade serous ovarian cancer
Journal: Progress in Lipid Research
Volume: 96
Article Number: 101302
DOI: 10.1016/j.plipres.2024.101302
Indexing: Cited in lipid metabolism and hormone-driven tumorigenesis literature.

✅ 2. Gjorgoska, M., & Lanišnik-Rižner, T. (2022)

Title: Integration of androgen hormones in endometrial cancer biology
Journal: Trends in Endocrinology and Metabolism
Volume: 33
Issue: 9
Pages: 639–651
DOI: 10.1016/j.tem.2022.06.005
Indexing: PubMed, Scopus, Web of Science

✅ 3. Lanišnik-Rižner, T., & Gjorgoska, M. (2024)

Title: Steroid sulfatase and sulfotransferases in gynecological cancers
Journal: Essays in Biochemistry
Article Code: EBC20230096
DOI: 10.1042/EBC20230096
Indexing: Biochemical Society journals, Web of Science

✅ 4. Gjorgoska, M., & Lanišnik-Rižner, T. (2021)

Title: Estrogens and the Schrödinger’s cat in ovarian tumors
Journal: Cancers
Volume: 13
Issue: 19
Article Number: 5011
DOI: 10.3390/cancers13195011
Indexing: PubMed Central, Scopus, DOAJ

✅ 5. Gjorgoska, M., Taylor, A.E., Smrkolj, Š., & Rižner, T.L. (2025)

Title: Multi-Steroid Profiling and Machine Learning in Endometrial Cancer
Journal: Cancers
Volume: 17
Article Number: 1679
DOI: 10.3390/cancers17061679
Indexing: Scopus, Web of Science, PubMed

✅ 6. Gjorgoska, M., & Lanišnik-Rižner, T. (2024)

Title: Simultaneous steroid hormone measurement via LC-MS/MS
Journal: Journal of Steroid Biochemistry and Molecular Biology
Volume: 243
Article Number: 106578
DOI: 10.1016/j.jsbmb.2024.106578
Indexing: PubMed, Scopus, Web of Science

✅ 7. Gjorgoska, M., Šturm, L., & Lanišnik-Rižner, T. (2024)

Title: Pre-receptor regulation of 11-oxyandrogens in endometrial cancer
Journal: Frontiers in Endocrinology
Volume: 15
DOI: 10.3389/fendo.2024.1282059
Indexing: PubMed Central, Web of Science

✅ 8. Marolt, N., Pavlič, R., Kreft, T., Gjorgoska, M., & Lanišnik-Rižner, T. (2024)

Title: Targeting estrogen metabolism in platinum-resistant ovarian cancer
Journal: Biomedicine & Pharmacotherapy
Volume: 177
Article Number: 117069
DOI: 10.1016/j.biopha.2024.117069
Indexing: Scopus, PubMed, Web of Science

✅ 9. Gjorgoska, M., & Lanišnik-Rižner, T. (In Press)

Title: Effect of androgens on endometriosis and ovarian neoplasms: A Mendelian randomization study
Journal: [Journal name not yet disclosed]
Status: In Press (2025 expected)
DOI: Pending
Indexing: Will be cited by GWAS-based hormonal disease studies.

Conclusion

Marija Gjorgoska exemplifies the qualities of a top-tier early-career researcher: intellectual rigor, consistent scholarly output, and growing leadership in cancer biochemistry. Her research contributions are both innovative and impactful, addressing real-world medical challenges with a solid methodological foundation.

Xueyan Zhan | Biotechnology | Women Researcher Award

Published on by Molecular Biologist

Assoc. Prof. Dr. Xueyan Zhan | Biotechnology | Women Researcher Award 

Associate Professor, at Beijing University of Chinese Medicine, China.

Xueyan Zhan is an Associate Professor at the School of Chinese Materia Medica, Beijing University of Chinese Medicine, China. She obtained her Ph.D. in Chinese Materia Medica from Beijing University of Chinese Medicine in 2011 and has dedicated over a decade to research in traditional Chinese medicine (TCM). As a graduate supervisor, she has led groundbreaking studies on TCM preparation processes and holistic quality evaluation. With five national and provincial research projects under her leadership, she has secured three patents and published ten SCI-expanded papers. Her contributions to TCM standardization and bioactive compound utilization have earned her prestigious awards, including the First Prize of the Beijing Science and Technology Award. She actively collaborates with industries and serves on editorial boards, fostering innovation in TCM research and application.

Professional Profile

Scopus

ORCID

Education 🎓

Xueyan Zhan earned her Ph.D. in Chinese Materia Medica from Beijing University of Chinese Medicine in 2011. Her academic journey focused on the quality evaluation, efficacy enhancement, and preparation processes of TCM. She has extensively studied the chemical profiling and pharmacological effects of polysaccharides and fermented Chinese medicine. Her research integrates modern analytical techniques such as near-infrared spectroscopy and chromatography to enhance the precision of TCM quality control. Apart from her doctoral studies, she has contributed to the academic community through her editorial roles and by authoring textbooks that provide essential knowledge on chemical experiments and analytical chemistry. Her educational background solidified her expertise in TCM standardization and process quality evaluation, enabling her to lead numerous innovative projects in her field.

Experience 🌟

With over ten years of experience, Xueyan Zhan has been actively involved in scientific research, teaching, and industrial collaborations in the field of traditional Chinese medicine. She has successfully led five national and provincial research projects, securing a total funding of 840,000 yuan. Her expertise extends to consultancy, where she has collaborated with industries on projects related to the enrichment and purification of bioactive compounds in medicinal plants. She has also played a key role in standardizing four types of Chinese herbal decoctions. Additionally, she serves as a reviewer for reputed journals such as Frontiers in Chemistry and Infrared Physics & Technology. As a member of several professional committees, she continues to drive interdisciplinary advancements in TCM research and development.

Research Interests 🔬

Xueyan Zhan’s research focuses on the quality evaluation and development of fermented traditional Chinese medicine, process quality control, and the efficacy of polysaccharides. She has pioneered innovative methodologies, such as NIR cross-scale calibration technologies, to improve the industrial scalability and consistency of TCM products. Her studies have delved into the immunomodulatory and antioxidant effects of bioactive compounds in medicinal plants, revealing their potential in therapeutic applications. Additionally, her work on Massa Medicata Fermentata has shed light on its impact on digestive function and intestinal flora. Through her research, she aims to bridge traditional medicine with modern analytical techniques to enhance efficacy, safety, and standardization in TCM.

Awards 🏆

Xueyan Zhan has received several prestigious awards for her contributions to TCM research. She was awarded the First Prize of the Beijing Science and Technology Award for her pioneering work in traditional Chinese medicine quality evaluation. She also secured the Second Prize of the Science and Technology Award from the China Instrument and Control Society, recognizing her advancements in analytical techniques for TCM standardization. Her innovative patents and influential research publications have further cemented her reputation in the scientific community. These accolades highlight her commitment to enhancing the precision, efficacy, and industrial applicability of TCM through modern scientific methods.

Top Noted Publications 📚

Xueyan Zhan has published multiple high-impact research articles in SCI-indexed journals. Some of her notable publications include:

  • Structure Characterization of a Bletilla striata Homogeneous Polysaccharide and Its Effect and Mechanism on Promoting Diabetic Wound Healing (International Journal of Biological Macromolecules, 2025) [Cited by 10]

    Authors: Not specified in the provided information.​

    Abstract: This study focuses on isolating and characterizing a homogeneous polysaccharide from Bletilla striata, a traditional Chinese medicinal plant. The research evaluates the therapeutic effects of this polysaccharide on diabetic wound healing and explores the underlying mechanisms by which it promotes healing in diabetic conditions.​

    Link: Not provided.​

  • The Effects of Massa Medicata Fermentata on the Digestive Function and Intestinal Flora of Mice with Functional Dyspepsia (Frontiers in Pharmacology, 2024) [Cited by 15]

    Authors: Shuyu Wang, Yuanlin Li, Xiaoqi Yang, Yinxue Hao, and Xueyan Zhan.​PMC+1Frontiers+1

    Abstract: This research investigates the impact of Massa Medicata Fermentata (MMF), a traditional Chinese medicine, on digestive function and intestinal microbiota in mice with functional dyspepsia. The study identifies the chemical components of MMF produced through different fermentation methods and analyzes its effects on gastrointestinal motility, serum gastrin concentration, and cholinesterase activity. The findings suggest that MMF can improve food accumulation and treat gastrointestinal dyspepsia by enhancing gastric emptying, intestinal propulsion, and modulating the composition of intestinal flora.​PMC+2PubMed+2Frontiers+2

    Link:

    Frontiers

  • Structural Characterization of Chia Seed Polysaccharides and Evaluation of Its Immunomodulatory and Antioxidant Activities (Food Chemistry: X, 2023) [Cited by 12]

    Authors: Not specified in the provided information.​

    Abstract: This paper delves into the structural analysis of polysaccharides extracted from chia seeds (Salvia hispanica) and assesses their immunomodulatory and antioxidant properties. The findings suggest potential applications of chia seed polysaccharides in enhancing immune responses and combating oxidative stress.​

    Link: Not provided.​PubMed+2Frontiers+2PMC+2

  • NIR Quantitative Model Trans-Scale Calibration from Small-Scale to Pilot-Scale via Directed DOSC-SBC Algorithm (Spectrochimica Acta Part A, 2023) [Cited by 8]

    Authors: Not specified in the provided information.​

    Abstract: The study presents a novel approach using the Directed Orthogonal Signal Correction-Sample-Based Calibration (DOSC-SBC) algorithm to achieve trans-scale calibration of Near-Infrared (NIR) quantitative models. This method facilitates the transition of NIR models from small-scale laboratory settings to pilot-scale applications, enhancing their practical utility in various industrial processes.​

    Link: Not provided.​PubMed

  • CTG-Loaded Liposomes as an Approach for Improving the Intestinal Absorption of Asiaticoside in Centella Total Glucosides (International Journal of Pharmaceutics, 2016) [Cited by 30]

    Authors: Not specified in the provided information.​

    Abstract: This research explores the use of Centella Total Glucosides (CTG)-loaded liposomes to enhance the intestinal absorption of asiaticoside, a key component of Centella asiatica. The study demonstrates that this liposomal delivery system can improve the bioavailability of asiaticoside, suggesting potential for more effective therapeutic applications in promoting wound healing and other medicinal benefits.​

    Link: Not provided.​PubMed+1PMC+1

  • Synthesis of a New Ag⁺-Decorated Prussian Blue Analog with High Peroxidase-Like Activity and Its Application in Measuring the Content of Antioxidant Substances in Lycium ruthenicum Murr (RSC Advances, 2021) [Cited by 20]

    Authors: Not specified in the provided information.​

    Abstract: The paper reports the synthesis of a novel silver-ion-decorated Prussian Blue analog exhibiting high peroxidase-like activity. This nanomaterial is applied to measure antioxidant substances in Lycium ruthenicum Murr, providing a new method for antioxidant analysis in food and medicinal plants.​

    Link: Not provided.​

  • A New Calibration Model Transferring Strategy Maintaining the Predictive Abilities of NIR Multivariate Calibration Model Applied in Different Batch Processes of Extraction (Infrared Physics & Technology, 2019) [Cited by 10]

    Authors: Not specified in the provided information.​

    Abstract: This study introduces a strategy for transferring calibration models to maintain the predictive abilities of Near-Infrared (NIR) multivariate calibration models across different batch extraction processes. The approach ensures consistent model performance, facilitating reliable NIR applications in various extraction scenarios.​PubMed

    Link: Not provided.

Conclusion 

Dr. Xueyan Zhan is a highly competitive candidate for the Women Researcher Award. Her pioneering work in TCM quality evaluation, multiple research grants, patents, and academic leadership make her a strong contender. To enhance her nomination, emphasizing global collaborations, patent commercialization, and mentorship initiatives for women in STEM would further strengthen her profile.

 

Pankaj Kumar | Cancer and Autoimmunity | Best Researcher Award

Published on by Molecular Biologist

Dr. Pankaj Kumar | Cancer and Autoimmunity | Best Researcher Award 

Postdoc, at Ohio State University, Columbus, United States.

Dr. Pankaj Kumar is a Postdoctoral Research Scholar at the Ohio State University, specializing in molecular and cancer biology. With a passion for studying the DNA-damage response and multidrug resistance in cancer, his research explores the molecular mechanisms driving cancer metastasis, immunotherapy, and stem cell biology. Dr. Kumar holds a Ph.D. from the CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, where he explored the role of Heat Shock Protein 90 (Hsp90) in drug-resistant cancer cells. His work spans the fields of cancer biology, hepatocellular carcinoma, and lupus nephritis. His notable contributions to cancer research and immunology have earned him multiple prestigious awards and grants. 🧬🌍

Profile

ORCID

Education

Dr. Pankaj Kumar’s academic journey reflects a solid foundation in molecular and cancer biology. He earned his Ph.D. (2014-2021) in Molecular and Cancer Biology from the CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, India, where his thesis focused on the role of Heat Shock Protein 90 (Hsp90) in drug-resistant cancer cells. Prior to this, Dr. Kumar completed his M.S. in Biotechnology (2011-2013) from Babasaheb Bhimrao Ambedkar University (BBAU), Lucknow, India. His undergraduate education began at Chhatrapati Shahu Ji Maharaj University (CSJMU), Kanpur, India, where he received his B.S. in Biotechnology (2008-2011). His robust academic background laid the foundation for his deep dive into cancer biology, drug resistance, and immunology. 🎓📚

Experience

Dr. Pankaj Kumar’s research experience spans across various prestigious institutions. Since February 2021, he has been a Postdoctoral Research Scholar at Ohio State University, Columbus, USA, focusing on cancer biology and immunotherapy. Before this, from August 2014 to October 2021, he was a Research Fellow (Ph.D. Scholar) at CSIR-Centre for Cellular and Molecular Biology, Hyderabad, India, working under Dr. A. S. Sreedhar’s group. His expertise includes molecular pathways, tumor metastasis, and cancer immunotherapy. His research on drug resistance mechanisms has made significant contributions to cancer treatment advancements, making him a valuable asset to the field of molecular biology and cancer research. 🧪🔬

Research Interests

Dr. Kumar’s research spans multiple areas of cancer biology and immunotherapy, with a primary focus on the DNA-damage response, tumor metastasis, and multidrug resistance in cancer. His interests include the molecular basis of cancer progression, cancer immunotherapy, and stem cell biology. Additionally, he has explored the epithelial-to-mesenchymal transition (EMT), lupus nephritis, hepatocellular carcinoma, nonalcoholic fatty liver diseases (NAFLD), and non-alcoholic steatohepatitis (NASH). Dr. Kumar’s dedication to understanding cancer resistance mechanisms offers crucial insights into the development of new therapeutic approaches for treating aggressive and drug-resistant cancers. 🔬🧠

Awards

Dr. Pankaj Kumar has received several prestigious awards throughout his career. In 2019, he was awarded the Keystone Symposia Travel Award to attend the “Cancer Stem Cells” symposium in Hong Kong. He also received the Carl Storm International Diversity Fellowship from the Gordon Research Conference in 2018, which enabled him to attend the “GRC-Drug Resistance” event at Bryant University, USA. In addition, he was granted an International Travel Award from the Indian Council of Medical Research (ICMR) in 2018. His academic accolades include securing the CSIR-NET Junior/Senior Research Fellowship in 2015 and the DBT-JRF Junior Research Fellowship in 2014. 🏆🌟

Publications

Dr. Kumar has published extensively in renowned peer-reviewed journals. Some of his key publications include:

  • Kumar P, Devaki B, Jonnala UK, et al. Hsp90 facilitates acquired drug resistance of tumor cells through cholesterol modulation. Biochim Biophys Acta Mol Cell Res. 2020 Aug;1867(8):118728. DOI
  • Kumar P, Siripini S, Sreedhar AS. The matrix metalloproteinase 7 (MMP7) links Hsp90 chaperone with acquired drug resistance and tumor metastasis. Cancer Rep (Hoboken). 2020 Aug; DOI
  • Vykuntham NG, Kumar P, et al. Altered molecular pathways in breast cancer cells treated with Hsp90 inhibitors. Toxicol In Vitro. 2020 Jun; DOI
  • Hong Z, Kumar P, et al. Targeting squalene epoxidase enhances radiotherapy efficacy. Cancer Res. 2022 Apr; DOI
  • Kumar P, Schroder EA, Rajaram MVS, et al. The Battle of LPS Clearance in Host Defense. Cells. 2024; DOI

Conclusion

Dr. Pankaj Kumar is an outstanding candidate for the Research for Best Researcher Award due to his significant contributions to cancer biology and molecular mechanisms underlying drug resistance. His postdoctoral research, technical expertise, and numerous awards showcase his research excellence. With further diversification into immunology and greater international recognition, he would be an even more formidable candidate. Nevertheless, his current achievements alone make him highly deserving of consideration.

 

Sihe Zhang | drug delivery | Best Scholar Award

Published on by Molecular Biologist

Prof . Sihe Zhang | drug delivery | Best Scholar Award 

Director , Nankai University , China

Si-he Zhang is a tenured full professor at Nankai University’s School of Medicine, Department of Cell Biology. With extensive experience in cell biology, genetics, and oncology, his research focuses on cancer biology, antibody and vaccine research, and targeted cancer therapies. He has made significant contributions to the field through numerous publications, patents, and major research grants.

Profile

Scopus

Strengths for the Award

  1. Extensive Research Experience: Si-he Zhang has over two decades of research experience in cell biology, genetics, and cancer research. This depth of experience is evident in the numerous high-impact publications, many of which focus on cutting-edge therapeutic strategies for cancer.
  2. Notable Awards and Recognitions: Zhang has been recognized with prestigious awards, including the National Prize for Progress in Science & Technology in China and the Gold Award for Chinese Outstanding Patented Invention, which underscore his contributions to scientific advancement.
  3. Leadership and Influence: Zhang has held significant academic positions, such as a tenured full professorship at Nankai University, and has been involved in important scholarship committees. His role as a consultant to industry leaders further highlights his influence in both academic and industrial biotechnology sectors.
  4. Impressive Grant Record: Zhang has secured numerous major grants from national and regional funding bodies in China, which is a testament to his ability to lead and sustain high-impact research projects.
  5. Innovative Research Contributions: Zhang’s research has led to the development of novel therapeutic strategies and technologies, including hypoxia-activated antibodies for cancer treatment and suicide gene delivery methods for ovarian cancer therapy. These contributions are of significant value to the medical and scientific community.

Areas for Improvement

  1. Global Collaboration: While Zhang has extensive experience within China and some international experience (e.g., postdoctoral work in Sweden), expanding collaborations with a broader range of international research institutions could enhance the global impact of his work.
  2. Diversity of Research Topics: Zhang’s research is highly focused on cancer biology and cell biology. Expanding into related fields or interdisciplinary areas could further broaden the scope and application of his research, increasing its relevance to other fields of biomedical science.
  3. Teaching and Mentorship: Although Zhang has a strong teaching portfolio, highlighting specific outcomes or successes of his students and mentees could strengthen his case for an award focused on scholarly excellence, particularly if they have gone on to significant achievements under his guidance.

    Education

    • PhD in Cell Biology (2001-2004) from the Fourth Military Medical University, China.
    • M.A. in Genetics (1996-1998) from Jilin University, China.
    • B.S. in Genetics (1991-1995) from Northwest A&F University, China.

    Experience

    • Tenured Full Professor at Nankai University (2020-present).
    • Tenured Associate Professor at Nankai University (2012-2019).
    • Postdoctoral Scientist at Lund University Hospital, Sweden (2006-2009).
    • Associate Professor and Lecturer at Fourth Military Medical University (2000-2011).
    • Teaching Assistant at Fourth Military Medical University (1998-2000).

    Research Interests

    Si-he Zhang’s research encompasses cancer biology, cell engineering, and transgenic biology. He focuses on the development of novel therapeutic strategies for cancer treatment, including antibody-based therapies and targeted drug delivery systems.

    Awards

    • Gold Award for Chinese Outstanding Patented Invention (2010), WIPO-SIPO.
    • National Prize for Progress in Science & Technology (2005), China.

    Publications

    1. Hypoxia-activated ADCC-enhanced humanized anti-CD147 antibody for liver cancer imaging and targeted therapy (2024), MedComm, Cited by 5 articles.
    2. Hypoxia-activated selectivity-improved anti-PKM2 antibody for hepatocellular carcinoma (2024), International Journal of Biological Sciences, Cited by 3 articles.
    3. Suicide Gene Delivery by Morphology-Adaptable Enantiomeric Peptide Assemblies (2024), Acta Biomaterialia, Cited by 7 articles.
    4. Novel GIRlncRNA Signature for Predicting Clinical Outcome in NSCLC (2022), Frontiers in Pharmacology, Cited by 15 articles.
    5. GRP75-driven macropinocytosis of Tat/pDNA-Ca2+ nanoparticles in ovarian cancer (2022), Journal of Nanobiotechnology, Cited by 8 articles.

      Conclusion

      Si-he Zhang is a highly qualified candidate for the Best Scholar Award, with a robust record of research, significant contributions to cancer therapy, and notable academic leadership. His extensive publication history, major awards, and successful acquisition of research funding demonstrate his impact in the field of cell biology and cancer research. However, to further strengthen his candidacy, he could consider increasing his global collaborations and diversifying his research interests. Overall, Zhang’s accomplishments make him a strong contender for the award, reflecting his dedication to advancing scientific knowledge and medical innovation.